The financials
Thermo Fisher Scientific by the numbers
Thermo Fisher Scientific (TMO) reported revenue of $12.0B in Q2 2026 (quarter ended June 27, 2026), up 10% from the same quarter a year earlier. That came with net income of $1.74B (14% of revenue). For the full year FY2025, revenue was $44.6B (+3.9% year on year) and net income $6.70B. Its largest segment in 2026-Q2 was Life Sciences Solutions at $1.06B, 38% of the disclosed total, just ahead of Analytical Instruments at 30%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $12.0B | $10.9B | +10% |
| Operating income | $2.09B | $1.83B | +14% |
| Net income | $1.74B | $1.62B | +7.4% |
| Diluted EPS | $4.68 | $4.28 | +9.3% |
| Operating | Revenue | Share |
|---|---|---|
| Life Sciences Solutions | $1.06B | 38% |
| Analytical Instruments | $821M | 30% |
| Laboratory Products And Biopharma Services | $608M | 22% |
| Specialty Diagnostics | $290M | 10% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2026Total $2.78B (+6.1%)
Specialty Diagnostics grew +5.1% year on yearLife Sciences Solutions -1.4% year on year
Segment Latestquarter on quarteryear on year
- Life Sciences Solutions$1.06B$1.06BQoQ +8.1%year on year -1.4%+8.1%-1.4%
- Analytical Instruments$821.0M$821.0MQoQ +2.9%year on year +4.7%+2.9%+4.7%
- Laboratory Products And Biopharma Services$608.0M$608.0MQoQ +6.9%year on year +1.2%+6.9%+1.2%
- Specialty Diagnostics$290.0M$290.0MQoQ +7.0%year on year +5.1%+7.0%+5.1%
- Laboratory Products And Biopharma Services--QoQ -year on year ---
Diagnostics & Research
Ranks #9 of 29 by Smart Score